




# ANEURYSM REGRESSION WITH THE **GORE® EXCLUDER®** AAA ENDOPROSTHESIS

Recent studies<sup>1,2</sup> suggest there is an independent association between aneurysm sac behavior and patient mortality after EVAR. Deery et al., states that sac regression predicted a decrease in late mortality and O'Donnell et al., states that any failure of the sac to regress is associated with higher long-term mortality, independent of reinterventions or endoleaks.

Data from the Global Registry for Endovascular Aortic Treatment (GREAT) shows that AAA's treated with the GORE® EXCLUDER® AAA Endoprosthesis compare favorably to one-year data from the Vascular Quality Initiative (VQI). In the VQI analysis of 14,817 patients done by O'Donnell et al., 40% of AAA sacs regressed, 35% remained stable and 25% expanded.<sup>2</sup>

**Change in aneurysm sac diameter (mm) in patients treated with the GORE® EXCLUDER® AAA Device**



The change in aneurysm sac diameter (mm) from the baseline (one month) measurement is shown at each year follow-up (FU) window, up to the five year FU window.

# Durable Outcomes. Proven Performance.

The GORE® EXCLUDER® AAA Device is associated with low reintervention rates, a 71.1% freedom from all-cause mortality\* through 5 years and has been proven through clinical trials, registries and site reported use, to be a safe, effective and durable solution, earning the trust of physicians worldwide.

## GORE® EXCLUDER® AAA Device data from GREAT†

Length of follow-up (through)	5 years
Number of patients possible	3,274
Freedom from aneurysm-related mortality	98.8%
Freedom from all reintervention	92.0%
Freedom from device related reintervention	94.7%
Conversion to open repair	0.8%
Aneurysm-related rupture	0.3%
Migration‡	0.0%
Type Ia endoleak	0.9%
Type Ib endoleak	0.7%
Type III endoleak	0.2%
Limb occlusion	0.7%
Renal complication§	0.4%

\* Kaplan Meier estimate of Freedom from Mortality of 71.1% with a 95% CI of 68.5–73.5%. Analysis is a point estimate through 5 years.


† To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site reported serious adverse events. Therefore, all reported endoleaks are defined as serious and require reintervention.

‡ One peri-procedural migration reported. Zero migrations reported during follow-up through 5 years.

§ Inclusion for renal complication rate: Subjects with renal complication were identified with MedDRA code. Of those identified with MedDRA code as having a renal complication, only those who showed the SAE occurring within 75 days of the procedure AND were reported by the site/physician as being related to the device or procedure were included in the renal complication rate.

1. Deery SE, Ergul EA, Schermerhorn ML, Siracuse JJ, Schanzer A, Goodney PP, *et al.* Aneurysm sac expansion is independently associated with late mortality in patients treated with endovascular aneurysm repair. *Journal of Vascular Surgery* 2018;67:157-64.
2. O'Donnell TFX, Deery SE, Boitano LT, *et al.* Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival. *Journal of Vascular Surgery* 2019;69:414-422.

 Consult Instructions  
for Use  
[eifu.goremedical.com](http://eifu.goremedical.com)

Refer to *Instructions for Use* at [eifu.goremedical.com](http://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.  **Rx Only**  
Products listed may not be available in all markets.

GORE, *Together, improving life*, EXCLUDER and designs are trademarks of W. L. Gore & Associates.  
© 2020 W. L. Gore & Associates, Inc. AZ1395-EN2 AUGUST 2020

---

Contact your local  
Field Sales Associate  
for more information

---

W. L. Gore & Associates, Inc.  
[goremedical.com](http://goremedical.com)

Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673  
United States Flagstaff, AZ 86003 800 437 8181 928 779 2771

